• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感觉运动感知康复综合(SPRInt)计划:使用肉毒毒素增强运动反馈的运动练习治疗特发性颈肌张力障碍——一项观察性研究。

Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) program: exercises with augmented movement feedback associated to botulinum neurotoxin in idiopathic cervical dystonia-an observational study.

机构信息

U. O. di Recupero e Rieducazione Funzionale, I.R.C.C.S. Fondazione Don Carlo Gnocchi Onlus, via Alfonso Capecelatro 66, 20148, Milan, Italy.

U. O. di Medicina riabilitativa e neuroriabilitazione, Ospedale Niguarda, Milan, Italy.

出版信息

Neurol Sci. 2020 Jan;41(1):131-138. doi: 10.1007/s10072-019-04061-5. Epub 2019 Sep 2.

DOI:10.1007/s10072-019-04061-5
PMID:31478151
Abstract

BACKGROUND

Idiopathic cervical dystonia (ICD) is a focal dystonia affecting neck muscles. Botulinum neurotoxin (BoNT) is the first-line treatment of ICD and different physical therapies (including exercise) are often proposed as adjunct treatments. However, the actual effectiveness of exercise in ICD is unclear. The aim of the current work is to assess the potential effectiveness of the Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) exercise program as adjunct therapy for ICD.

METHODS

Fifteen ICD patients received BoNT injections in the neck muscles and, 12 weeks later, received BoNT a second time and SPRInt started. SPRInt consists in 18 exercise sessions in which augmented feedback of movement (including visual and acoustic feedback) is extensively used. Dystonia burden was measured by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Patients were evaluated immediately before, 6 and 12 weeks after each BoNT injection.

RESULTS

Six weeks after the first BoNT injection (i.e., at BoNT peak effect), TWSTRS total score was better than baseline and remained improved at 12 weeks. TWSTRS disability domain slightly improved 6 weeks after the first BoNT injection, but after 6 more weeks returned to its baseline level. Disability improved more at SPRInt end (i.e., 6 weeks after the second BoNT injection), being even lower than after toxin alone. With a single-subject analysis, 4/10 patients who did not improve disability after BoNT improved after SPRInt plus BoNT.

CONCLUSIONS

SPRInt plus BoNT can be more effective than BoNT alone in improving cervical dystonia patients' difficulties in the activities of daily living.

TRIAL REGISTRATION

www.ClinicalTrials.gov, identifier NCT03247868 (https://register.clinicaltrials.gov).

摘要

背景

特发性颈肌张力障碍(ICD)是一种影响颈部肌肉的局灶性肌张力障碍。肉毒毒素(BoNT)是 ICD 的一线治疗方法,通常还会提出不同的物理治疗(包括运动)作为辅助治疗。然而,运动在 ICD 中的实际效果尚不清楚。目前这项工作的目的是评估 Sensorimotor Perceptive Rehabilitation Integrated(SPRInt)运动方案作为 ICD 辅助治疗的潜在效果。

方法

15 名 ICD 患者接受颈部肌肉 BoNT 注射,12 周后再次接受 BoNT 注射并开始 SPRInt。SPRInt 包括 18 节运动课程,其中广泛使用运动的增强反馈(包括视觉和听觉反馈)。肌张力障碍负担通过多伦多西部痉挛性斜颈评定量表(TWSTRS)进行测量。患者在每次 BoNT 注射前、注射后 6 周和 12 周进行评估。

结果

首次 BoNT 注射后 6 周(即 BoNT 效果峰值时),TWSTRS 总分优于基线水平,12 周时仍有改善。首次 BoNT 注射后 6 周,TWSTRS 残疾域略有改善,但 6 周后又恢复到基线水平。SPRInt 结束时(即第二次 BoNT 注射后 6 周)残疾改善更多,甚至低于单独使用毒素。通过单病例分析,4/10 名在 BoNT 后残疾无改善的患者在 SPRInt 加 BoNT 后有所改善。

结论

SPRInt 加 BoNT 比单独使用 BoNT 更能改善颈椎病患者日常生活活动的困难。

试验注册

www.ClinicalTrials.gov,标识符 NCT03247868(https://register.clinicaltrials.gov)。

相似文献

1
Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) program: exercises with augmented movement feedback associated to botulinum neurotoxin in idiopathic cervical dystonia-an observational study.感觉运动感知康复综合(SPRInt)计划:使用肉毒毒素增强运动反馈的运动练习治疗特发性颈肌张力障碍——一项观察性研究。
Neurol Sci. 2020 Jan;41(1):131-138. doi: 10.1007/s10072-019-04061-5. Epub 2019 Sep 2.
2
A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.一项肉毒毒素与肉毒毒素联合物理疗法治疗颈肌张力障碍的随机研究。
Parkinsonism Relat Disord. 2019 Jun;63:195-198. doi: 10.1016/j.parkreldis.2019.02.035. Epub 2019 Feb 25.
3
Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.基于运动学指导的个体化肉毒毒素 A 治疗颈肌张力障碍。
J Neurol. 2018 Jun;265(6):1269-1278. doi: 10.1007/s00415-018-8819-6. Epub 2018 Mar 20.
4
An analysis of the efficacy of botulinum neurotoxin type a in treating cervical dystonia.A型肉毒毒素治疗颈肌张力障碍的疗效分析。
Technol Health Care. 2024;32(4):2421-2430. doi: 10.3233/THC-231182.
5
The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.针对颈部肌张力障碍运动终板区的肉毒杆菌毒素注射的临床效用。
Eur J Neurol. 2014 Dec;21(12):1486-e98. doi: 10.1111/ene.12517. Epub 2014 Jul 24.
6
Study protocol: multimodal physiotherapy as an add-on treatment to botulinum neurotoxin type A therapy for patients with cervical dystonia: DysPT-multi-a prospective, multicentre, single-blind, randomized, controlled study.研究方案:多模态物理疗法作为 A 型肉毒毒素治疗颈肌张力障碍患者的附加治疗:DysPT-multi-前瞻性、多中心、单盲、随机、对照研究。
Trials. 2021 Oct 25;22(1):740. doi: 10.1186/s13063-021-05705-8.
7
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.NeuroBloc(B型肉毒毒素)治疗对A型肉毒毒素耐药的颈部肌张力障碍的安全性和有效性。
Neurology. 1999 Oct 22;53(7):1431-8. doi: 10.1212/wnl.53.7.1431.
8
Botulinum toxin type B for cervical dystonia.用于治疗颈部肌张力障碍的B型肉毒毒素
Cochrane Database Syst Rev. 2005 Jan 25(1):CD004315. doi: 10.1002/14651858.CD004315.pub2.
9
Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial.评估肉毒毒素注射治疗张力性手震颤:一项随机临床试验。
JAMA Neurol. 2021 Mar 1;78(3):302-311. doi: 10.1001/jamaneurol.2020.4766.
10
The effect of a single botulinum toxin treatment on somatosensory processing in idiopathic isolated cervical dystonia: an observational study.肉毒毒素单次治疗对特发性孤立性颈肌张力障碍患者躯体感觉处理的影响:一项观察性研究。
J Neurol. 2018 Nov;265(11):2672-2683. doi: 10.1007/s00415-018-9045-y. Epub 2018 Sep 8.

引用本文的文献

1
Neurorehabilitation in Dystonia Care: Key Questions of Who Benefits, What Modalities, and When to Intervene.肌张力障碍治疗中的神经康复:谁将受益、采用何种方式以及何时干预的关键问题
Dystonia. 2025;4. doi: 10.3389/dyst.2025.14695. Epub 2025 Aug 22.
2
The Application of Goal Attainment Scaling in Cervical Dystonia - An Exploratory Observational Pilot Study.《目标达成评定量表在颈肌张力障碍中的应用——一项探索性观察性初步研究》。
Mov Disord Clin Pract. 2024 Aug;11(8):1013-1017. doi: 10.1002/mdc3.14118. Epub 2024 Jun 3.
3
The effectiveness of physiotherapy for patients with isolated cervical dystonia: an updated systematic review and meta-analysis.

本文引用的文献

1
Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance.肉毒杆菌神经毒素联合肌电图/超声引导治疗颈部肌张力障碍
Neurol Clin Pract. 2019 Feb;9(1):64-73. doi: 10.1212/CPJ.0000000000000568.
2
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study.注射用达昔布妥毒素A治疗颈部肌张力障碍:一项2期剂量递增多中心研究。
Mov Disord Clin Pract. 2018 Apr 26;5(3):273-282. doi: 10.1002/mdc3.12613. eCollection 2018 May-Jun.
3
Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.
物理疗法治疗孤立性颈肌张力障碍患者的疗效:更新的系统评价和荟萃分析。
BMC Neurol. 2024 Feb 1;24(1):53. doi: 10.1186/s12883-023-03473-3.
4
Diagnostic and therapeutic recommendations in adult dystonia: a joint document by the Italian Society of Neurology, the Italian Academy for the Study of Parkinson's Disease and Movement Disorders, and the Italian Network on Botulinum Toxin.成人肌张力障碍的诊断和治疗建议:意大利神经病学学会、意大利帕金森病和运动障碍学会以及意大利肉毒毒素网络联合文件。
Neurol Sci. 2022 Dec;43(12):6929-6945. doi: 10.1007/s10072-022-06424-x. Epub 2022 Oct 3.
5
Smoothness of movement in idiopathic cervical dystonia.特发性颈肌张力障碍运动的流畅性。
Sci Rep. 2022 Mar 24;12(1):5090. doi: 10.1038/s41598-022-09149-1.
6
How Do I Rehabilitate Patients with Cervical Dystonia Remotely?如何远程康复治疗痉挛性斜颈患者?
Mov Disord Clin Pract. 2021 Apr 27;8(5):820-821. doi: 10.1002/mdc3.13212. eCollection 2021 Jul.
7
Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization.女性的疼痛:对一个值得优先关注的相关临床问题的前瞻性综述
Pain Ther. 2021 Jun;10(1):287-314. doi: 10.1007/s40122-021-00244-1. Epub 2021 Mar 15.
8
Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases.欧洲罕见运动障碍的管理:欧洲罕见神经疾病参考网络调查结果
Eur J Neurol. 2020 Aug;27(8):1493-1500. doi: 10.1111/ene.14302. Epub 2020 Jun 19.
走向针对局灶性肌张力障碍和痉挛的灵活且个性化肉毒杆菌神经毒素给药方案——近期研究见解
Toxicon. 2018 Jun 1;147:100-106. doi: 10.1016/j.toxicon.2018.01.018. Epub 2018 Jan 31.
4
Botulinum toxin type A therapy for cervical dystonia.A型肉毒毒素治疗颈部肌张力障碍
Cochrane Database Syst Rev. 2017 Dec 12;12(12):CD003633. doi: 10.1002/14651858.CD003633.pub3.
5
Cervical sensorimotor control in idiopathic cervical dystonia: A cross-sectional study.特发性颈肌张力障碍患者的颈椎运动感觉控制:一项横断面研究。
Brain Behav. 2017 Aug 11;7(9):e00735. doi: 10.1002/brb3.735. eCollection 2017 Sep.
6
The Italian Dystonia Registry: rationale, design and preliminary findings.意大利肌张力障碍登记处:基本原理、设计与初步结果。
Neurol Sci. 2017 May;38(5):819-825. doi: 10.1007/s10072-017-2839-3. Epub 2017 Feb 18.
7
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.A型肉毒杆菌毒素与B型肉毒杆菌毒素治疗颈部肌张力障碍的比较。
Cochrane Database Syst Rev. 2016 Oct 26;10(10):CD004314. doi: 10.1002/14651858.CD004314.pub3.
8
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia.追求更多美好时光:患者对肉毒杆菌毒素治疗颈部肌张力障碍的看法。
Patient Prefer Adherence. 2016 Aug 22;10:1601-8. doi: 10.2147/PPA.S106560. eCollection 2016.
9
Is my patient actually getting better? Application of the McNemar test for demonstrating the change at a single subject level.我的患者真的在好转吗?应用麦克尼马尔检验以在个体水平上证明变化。
Disabil Rehabil. 2017 Jun;39(13):1341-1347. doi: 10.1080/09638288.2016.1194486. Epub 2016 Jun 26.
10
Cervical dystonia: a neural integrator disorder.颈肌张力障碍:一种神经整合器障碍。
Brain. 2016 Oct;139(Pt 10):2590-2599. doi: 10.1093/brain/aww141. Epub 2016 Jun 20.